Unrestricted access to tenofovir, lamivudine, and dolutegravir as pre-exposure or post-exposure prophylaxis in community settings

Lancet Glob Health. 2023 Oct;11(10):e1494-e1495. doi: 10.1016/S2214-109X(23)00423-0.

Authors

Lynda Stranix-Chibanda¹, Tsungai Mhembere²

Affiliations

¹ Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe; University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe. Electronic address: lstranix@uz-ctrc.org.
² University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

PMID: 37734786
DOI: 10.1016/S2214-109X(23)00423-0

No abstract available

Publication types

Comment

MeSH terms

Heterocyclic Compounds, 3-Ring
Humans
Lamivudine*
Post-Exposure Prophylaxis*
Tenofovir

Substances

dolutegravir
Lamivudine
Tenofovir
Heterocyclic Compounds, 3-Ring